Previous Close | 1.0800 |
Open | 1.0700 |
Bid | 1.0600 x 400 |
Ask | 1.0900 x 400 |
Day's Range | 1.0700 - 1.0890 |
52 Week Range | 0.8800 - 3.3900 |
Volume | |
Avg. Volume | 255,577 |
Market Cap | 80.699M |
Beta (5Y Monthly) | 1.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2900 |
Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.80 |
Presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One ...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, May 15, 2024. A total of 41.34% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.